Skip to main content
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Latest Issue
Issue Archive
Special Issues
Web Exclusives
Special Series
Conference Correspondent
ASH 2023 - CLL
Ovarian Cancer Overview
Multimedia
All Videos
Interview with the Innovators
Quick Quiz
Subscribe
Tuesday, December 15, 2015 Presented by Ali McBride
Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
This peer-delivered program, brought to you by Takeda, will include a clinical overview of NINLARO and its product attributes.
View all Webinar Programs
Related Items
An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS, BCPS
Videos
Interview with the Innovators
,
Video
,
Ovarian Cancer
Immunotherapy in Combination with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
By
Amina Ahmed, MD
;
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS, BCPS
Videos
Interview with the Innovators
,
Video
Adverse Events and Improvements in Quality of Life Associated with First-Line Maintenance Therapy in Ovarian Cancer
By
Paula Anastasia, RN, MN, AOCN
;
Ali McBride, PharmD, MS, BCPS
Videos
Interview with the Innovators
,
Video
Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
By
Ali McBride, PharmD, MS, BCPS
;
Paula Anastasia, RN, MN, AOCN
Videos
Interview with the Innovators
,
Video